@article{94e7972758af466ca856a42f0628ee84,
title = "Neuropsychiatric adverse events and oseltamivir for prophylaxis",
author = "Mark Jones and Rokuro Hama and Tom Jefferson and Peter Doshi",
note = "Funding Information: All four authors are investigators for a UK National Institute of Health Research grant for a systematic review of neuraminidase inhibitors. Rokuro Hama provided scientific opinions on 11 adverse reaction cases related to oseltamivir following application by their families for adverse event compensation, and he receives royalties from two books published in 2008 titled {\textquoteleft}{\textquoteleft}Tamiflu: harmful as was afraid{\textquoteright}{\textquoteright} and {\textquoteleft}{\textquoteleft}In order to escape from drug-induced encephalopathy{\textquoteright}{\textquoteright}. Tom Jefferson was an ad hoc consultant for F. Hoffman-La Roche Ltd in 1998–9. He receives royalties from his books published by Blackwell and Il Pensiero Scientifico Editore, none of which are on neuraminidase inhibitors. He is occasionally interviewed by market research companies for anonymous interviews about phase 1 or 2 products. He is a consultant in a legal case regarding oseltamivir. Peter Doshi is funded by an institutional training grant from the Agency for Healthcare Research and Quality, number T32HS019488. He received h1500 from the European Respiratory Society in support of his travel to the 2012 European Respiratory Society annual congress where he gave an invited talk on oseltamivir.",
year = "2012",
doi = "10.2165/11641690-000000000-00000",
language = "English",
volume = "35",
pages = "1187--1188",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis",
number = "12",
}